Program
trastuzumab envedotin
Also written as “DP303c”, “DP303c injection” and “DP303c treatment”.
Its studies are mostly in Breast Neoplasms · Ovarian Neoplasms · Stomach Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Group | 62 open or running | phase 3since Jun 4, 2023 | Mar 22, 2021 | none ahead |
| Shanghai Runshi Pharmaceutical Technology | 11 open or running | phase 2since Aug 21, 2024 | Aug 21, 2024 | none ahead |
- Named in CSPC Pharmaceutical Group’s own pipeline as
trastuzumab envedotin
, phase 4, as of Aug 20, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 22, 2021First studies: 2 phase 2 studiesNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT04826107, NCT04828616
- Mar 27, 2022Phase 2 study in HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT05334810 · 191 enrolled
- Mar 14, 2023Phase 1 study in HER2-positive Advanced Solid TumorsCSPC Pharmaceutical Group · NCT05810103 · 12 enrolled · China
- Jun 4, 2023Phase 3 study in HER2-positive Advanced Breast CancerCSPC Pharmaceutical Group · NCT05901935 · 420 planned
- Mar 1, 2024Phase 3 study in HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT06313086 · 442 planned · China
- Aug 21, 2024Shanghai Runshi Pharmaceutical Technology’s first study: phase 2 study in Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaNew to Shanghai Runshi Pharmaceutical TechnologyShanghai Runshi Pharmaceutical Technology · NCT06577376 · 252 planned
TargetBeta
“An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized immunoglobulin G1 (IgG1) a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) and site-specifically conjugated, via a cleavable linker, to the microtubule-disrupting cytotoxic agent mono…”NCIt, read by Claude
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06577376Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma | 2 | Not yet recruiting | Shanghai Runshi Pharmaceutical Technology | Aug 26, 2026 | 252 |
| NCT06313086HER2-positive Breast Cancer · China | 3 | Recruiting | CSPC Pharmaceutical Group | Dec 2025 | 442 |
| NCT05901935HER2-positive Advanced Breast Cancer | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Jan 2026 | 420 |
| NCT05810103HER2-positive Advanced Solid Tumors · China | 1 | UNKNOWN | CSPC Pharmaceutical Group | Dec 23, 2023 | 12 |
| NCT05334810HER2-positive Breast Cancer | 2 | UNKNOWN | CSPC Pharmaceutical Group | Dec 31, 2023 | 191 |
| NCT04828616Ovarian Neoplasms · China | 2 | UNKNOWN | CSPC Pharmaceutical Group | Jul 2023 | 104 |
| NCT04826107Stomach Neoplasms | 2 | UNKNOWN | CSPC Pharmaceutical Group | Aug 2024 | 196 |
How it is read
Names in the registry
- “DP303c”, 5 entries
- “DP303c injection”, 1 entry
- “DP303c treatment”, 1 entry
- “DP303c treatment(second-line of HER2-positive)”, 1 entry
- “DP303c treatment (third-line of HER2-positive)”, 1 entry
Codes read as this program: DP303C.
Conditions, from the studies’ own filings
- Breast Neoplasms, 3 studies
- Ovarian Neoplasms, 1 study
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.